Mostrar el registro sencillo de la publicación

dc.contributor.authorPetermann-Rocha, Fanny
dc.contributor.authorHo, Frederick
dc.contributor.authorWelsh, Paul
dc.contributor.authorMackay, Daniel
dc.contributor.authorBrown, Rosemary E.
dc.contributor.authorGill, Jason M.R.
dc.contributor.authorSattar, Naveed
dc.contributor.authorGray, S.R.
dc.contributor.authorPell, J.P.
dc.contributor.authorCelis-Morales, Carlos
dc.date.accessioned2020-11-09T13:53:23Z
dc.date.available2020-11-09T13:53:23Z
dc.date.issued2020
dc.identifier.urihttp://repositorio.ucm.cl/handle/ucm/3173
dc.description.abstractIntroduction: It is unclear what combinations of physical capability markers used to define sarcopenia have the strongest associations with health outcomes. Aim: To compare the associations between different combinations of physical capability markers of sarcopenia with cardiovascular and respiratory outcomes and all-cause mortality. Study design: 469,830 UK Biobank participants were included in this prospective study. Four groups were derived based on combinations of three physical capability markers used to define sarcopenia or severe sarcopenia: gait speed, grip strength and muscle mass. Outcomes studied were all-cause mortality, as well as incidence and mortality from cardiovascular disease (CVD), respiratory disease and chronic obstructive pulmonary disease (COPD). Results: All combinations of physical capability markers used to define sarcopenia or severe sarcopenia identified individuals at increased risk of respiratory disease and all-cause mortality. However, the definition most strongly associated with a wide range of adverse health outcomes was the combination of slow gait speed plus low muscle mass, followed by severe sarcopenia, and the combination of slow gait speed plus low grip strength. The current definition of sarcopenia (low grip strength plus low muscle mass) had the weakest associations with all-cause (HR: 1.35 [95% CI: 1.07 to 1.71]) and respiratory mortality (HR: 1.88 [95% CI: 1.15 to 3.10]), as well as respiratory disease (HR: 1.38 [95% CI: 1.11 to 1.73]) and COPD incidence (HR: 2.08 [95% CI: 1.14 to 3.79]). Conclusions: Associations of sarcopenia with adverse outcomes were strongest when sarcopenia was defined as slow gait speed plus low muscle mass, followed by severe sarcopenia, suggesting that this combination of physical capability markers should be still considered in the diagnosis of sarcopenia.es_CL
dc.language.isoenes_CL
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
dc.sourceMaturitas, 138, 69-75es_CL
dc.subjectMortalityes_CL
dc.subjectIncidencees_CL
dc.subjectMuscle strengthes_CL
dc.subjectEWGSOP2es_CL
dc.titlePhysical capability markers used to define sarcopenia and their association with cardiovascular and respiratory outcomes and all-cause mortality: a prospective study from UK biobankes_CL
dc.typeArticlees_CL
dc.ucm.indexacionScopuses_CL
dc.ucm.indexacionIsies_CL
dc.ucm.urisibib2.ucm.cl:2048/login?url=https://www.sciencedirect.com/science/article/abs/pii/S0378512220302474es_CL
dc.ucm.doidoi.org/10.1016/j.maturitas.2020.04.017es_CL


Ficheros en la publicación

FicherosTamañoFormatoVer

No hay ficheros asociados a esta publicación.

Esta publicación aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo de la publicación

Atribución-NoComercial-SinDerivadas 3.0 Chile
Excepto si se señala otra cosa, la licencia de la publicación se describe como Atribución-NoComercial-SinDerivadas 3.0 Chile